REG - Avacta Group PLC - Block Listing Six Monthly Return

AvactaAnnouncement

26/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240426:nRSZ1211Ma&default-theme=true

RNS Number : 1211M  Avacta Group PLC  26 April 2024

 

 

 

 

 

 

26 April 2024

 

Avacta Group plc

 

("Avacta" or "the Group" or "the Company")

 

Block Listing Six Monthly Return

 

 

Avacta Group plc (AIM: AVCT), a life sciences developing innovative, targeted
oncology drugs and powerful diagnostics, today makes the following
notification pursuant to Schedule Six of the AIM Rules for Companies regarding
its existing block admission arrangements:

 

 Name of applicant:                                                                  Avacta Group plc
 Name of scheme:                                                                     EMI scheme
 Period of return:                         From:                                     28 October 2023          27 April 2024
 Balance of unallotted securities under scheme(s) from previous return:              797,922
 Plus:   The amount by which the block scheme(s) has been increased since            113,808
 the date of the last return (if any increase has been applied for):
 Less:   Number of securities issued/allotted under scheme(s) during                 108,724
 period (see LR3.5.7G):
 Equals:   Balance under scheme(s) not yet issued/allotted at end of period:         911,730

 

 Name of applicant:                                                                  Avacta Group plc
 Name of scheme:                                                                     LTIP scheme
 Period of return:                         From:                                     28 October 2023          27 April 2024
 Balance of unallotted securities under scheme(s):                                   5,277,257
 Plus:   The amount by which the block scheme(s) has been increased since            6,500,000
 the date of the last return (if any increase has been applied for):
 Less:   Number of securities issued/allotted under scheme(s) during                 2,058,000
 period (see LR3.5.7G):
 Equals:   Balance under scheme(s) not yet issued/allotted at end of period:         11,777,257

 

 Name of contact:              Tony Gardiner, Company Secretary
 Telephone number of contact:  + 44 (0) 1904 217070

 

Ends-

 

 

For further information from Avacta Group plc, please contact:

 

 Avacta Group plc                                                           Tel: +44 (0) 1904 21 7070

 Alastair Smith, Chief Executive Officer                                    www.avacta.com (http://www.avacta.com)

 Tony Gardiner, Chief Financial Officer

 Michael Vinegrad, Group Communications Director

 Stifel Nicolaus Europe Limited (Nomad and Joint Corporate Broker)          Tel: +44 (0) 207 710 7600

 Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / Ben Good   www.stifel.com (http://www.stifel.com/)

 Peel Hunt (Joint Corporate Broker)                                         Tel: +44 (0) 207 418 8900

 James Steel / Chris Golden / Patrick Birkholm                              www.peelhunt.com (http://www.peelhunt.com)

 ICR Consilium (Media and IR)                                               avacta@consilium-comms.com (mailto:avacta@consilium-comms.com)

 Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji

 

 

About Avacta Group plc - https://www.avacta.com (https://www.avacta.com/)

Avacta Group is a UK-based life sciences company focused on improving
healthcare outcomes through targeted cancer treatments and diagnostics.

Avacta has two divisions focused on therapeutics and diagnostics.

Avacta Therapeutics: a clinical stage oncology biotech division harnessing
proprietary therapeutic platforms to develop novel, highly targeted cancer
drugs.

Avacta Diagnostics: focused on supporting healthcare professionals and
broadening access to diagnostics.

Avacta has two proprietary platforms, pre|CISION™ and Affimer®.

The pre|CISION™ platform is a highly specific substrate for fibroblast
activation protein (FAP) which is upregulated in most solid tumours compared
with healthy tissues. The pre|CISION™ platform harnesses this tumour
specific protease to activate pre|CISION™ peptide drug conjugates and
pre|CISION™ antibody/Affimer® drug conjugates in the tumour
microenvironment, reducing systemic exposure and toxicity, allowing dosing to
be optimised to deliver the best outcomes for patients.

The lead pre|CISION™ programme AVA6000, a peptide drug conjugate form of
doxorubicin, is in Phase 1 studies. It has shown a dramatic improvement in
safety and tolerability in clinical trials to date compared with standard
doxorubicin and preliminary signs of clinical activity in multiple patients.

 

To register for news alerts by email go to
https://avacta.com/investors/investor-news-email-alerts/
(https://avacta.com/investors/investor-news-email-alerts/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRPPUAGCUPCPUA